Search research articles
Contact Us
Filters
Showing results (71-80 of 224) with videos related to
Page
of 23
Sort By:
Blood Neoplasia
|
June 30, 2026
Inhibition of PRMT5 sensitizes B-cell non-Hodgkin lymphoma cells to both intrinsic and extrinsic apoptotic cell death
Fen Zhu, Jing Wang, Christine E Ryan, et al.
Blood
|
September 8, 2012
Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia
Matthew S Davids, Jing Deng, Adrian Wiestner, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
April 20, 2010
Assessing surge capacity for radiation victims with marrow toxicity
Matthew S Davids, Cullen Case, Raymond Hornung, et al.
Leukemia Research
|
October 9, 2025
Evaluating complete response/remission rate as a surrogate endpoint in relapsed/refractory chronic lymphocytic leukemia
Lin Wang, Murat Kurt, Tim Disher, et al.
Haematologica
|
November 30, 2023
Pirtobrutinib <i>versus</i> venetoclax in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia: a matching-adjusted indirect comparison
Othman Al-Sawaf, Min-Hua Jen, Lisa M Hess, et al.
JAAD Case Reports
|
May 4, 2019
Psoriasiform eruptions secondary to phosphoinositide 3-kinase inhibition
Anna K Dewan, Sameer Gupta, Daniel Q Bach, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 2009
Response to a novel multitargeted tyrosine kinase inhibitor pazopanib in metastatic Merkel cell carcinoma
Matthew S Davids, Matthew Davids, Amanda Charlton, et al.
Future Oncology (London, England)
|
September 14, 2022
MAJIC: a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma
Christine E Ryan, Matthew S Davids, Richard Hermann, et al.
Pharmacoeconomics
|
May 9, 2020
Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States
Sang Kyu Cho, Beenish S Manzoor, Kavita R Sail, et al.
American Journal of Hematology
|
May 2, 2020
Management of CLL patients early in the COVID-19 pandemic: An international survey of CLL experts
Brian Koffman, Anthony Mato, John C Byrd, et al.
Page
of 23
Search research articles
Search
Showing results (71-80 of 224) with videos related to
Sort By:
Page
of 23
Blood Neoplasia
|
June 30, 2026
Inhibition of PRMT5 sensitizes B-cell non-Hodgkin lymphoma cells to both intrinsic and extrinsic apoptotic cell death
Fen Zhu, Jing Wang, Christine E Ryan, et al.
Blood
|
September 8, 2012
Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia
Matthew S Davids, Jing Deng, Adrian Wiestner, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
April 20, 2010
Assessing surge capacity for radiation victims with marrow toxicity
Matthew S Davids, Cullen Case, Raymond Hornung, et al.
Leukemia Research
|
October 9, 2025
Evaluating complete response/remission rate as a surrogate endpoint in relapsed/refractory chronic lymphocytic leukemia
Lin Wang, Murat Kurt, Tim Disher, et al.
Haematologica
|
November 30, 2023
Pirtobrutinib <i>versus</i> venetoclax in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia: a matching-adjusted indirect comparison
Othman Al-Sawaf, Min-Hua Jen, Lisa M Hess, et al.
JAAD Case Reports
|
May 4, 2019
Psoriasiform eruptions secondary to phosphoinositide 3-kinase inhibition
Anna K Dewan, Sameer Gupta, Daniel Q Bach, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 2009
Response to a novel multitargeted tyrosine kinase inhibitor pazopanib in metastatic Merkel cell carcinoma
Matthew S Davids, Matthew Davids, Amanda Charlton, et al.
Future Oncology (London, England)
|
September 14, 2022
MAJIC: a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma
Christine E Ryan, Matthew S Davids, Richard Hermann, et al.
Pharmacoeconomics
|
May 9, 2020
Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States
Sang Kyu Cho, Beenish S Manzoor, Kavita R Sail, et al.
American Journal of Hematology
|
May 2, 2020
Management of CLL patients early in the COVID-19 pandemic: An international survey of CLL experts
Brian Koffman, Anthony Mato, John C Byrd, et al.
Page
of 23